



Hepatology meets Infectiology – Chamäleon TBC

Akademisches Lehrkrankenhaus

am 11.09.2021

1. Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D: **The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.** *The Lancet Infectious diseases* 2016, **16**(11):1269-1278, DOI: 10.1016/s1473-3099(16)30216-x.
2. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A *et al*: **One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.** *N Engl J Med* 2019, **380**(11):1001-1011, DOI: 10.1056/NEJMoa1806808.
3. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ: **Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.** *N Engl J Med* 2014, **371**(17):1577-1587, DOI: 10.1056/NEJMoa1407426.
4. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J *et al*: **Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.** *N Engl J Med* 2021, **384**(18):1705-1718, DOI: 10.1056/NEJMoa2033400.
5. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I *et al*: **A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.** *N Engl J Med* 2019, **380**(13):1201-1213, DOI: 10.1056/NEJMoa1811867.
6. Roelens M, Battista Migliori G, Rozanova L, Estill J, Campbell JR, Cegielski JP, Tiberi S, Palmero D, Fox GJ, Guglielmetti L *et al*: **Evidence-based Definition for Extensively Drug-resistant Tuberculosis.** *American journal of respiratory and critical care medicine* 2021, DOI: 10.1164/rccm.202009-3527OC.
7. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J *et al*: **Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.** *N Engl J Med* 2020, **382**(10):893-902, DOI: 10.1056/NEJMoa1901814.
8. Cheng SL, Wang HC, Yang PC: **Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis.** *Int J Tuberc Lung Dis* 2007, **11**(12):1290-1295, DOI:
9. Brown CS, Smith CJ, Breen RA, Ormerod LP, Mittal R, Fisk M, Milburn HJ, Price NM, Bothamley GH, Lipman MC: **Determinants of treatment-related paradoxical reactions during anti-tuberculosis therapy: a case control study.** *BMC Infect Dis* 2016, **16**:479, DOI: 10.1186/s12879-016-1816-4.



10. Carvalho AC, De Iaco G, Saleri N, Pini A, Capone S, Manfrin M, Matteelli A: **Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients.** *Clin Infect Dis* 2006, **42**(6):893-895, DOI: 10.1086/500459.
11. Hawkey CR, Yap T, Pereira J, Moore DA, Davidson RN, Pasvol G, Kon OM, Wall RA, Wilkinson RJ: **Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis.** *Clin Infect Dis* 2005, **40**(9):1368-1371, DOI: 10.1086/429317.
12. Garcia Vidal C, Garau J: **Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis.** *Clin Infect Dis* 2005, **41**(6):915-916; author reply 916-917, DOI: 10.1086/432807.
13. Machida A, Ishihara T, Amano E, Otsu S: **Late-onset paradoxical reactions 10 years after treatment for tuberculous meningitis in an HIV-negative patient: a case report.** *BMC Infect Dis* 2018, **18**(1):313, DOI: 10.1186/s12879-018-3229-z.
14. de Martino M, Galli L, Chiappini E: **Reflections on the immunology of tuberculosis: will we ever unravel the skein?** *BMC Infect Dis* 2014, **14** Suppl 1:S1, DOI: 10.1186/1471-2334-14-S1-S1.